Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30 Research
  • [Research] Samsung SDI (006400) – IBK Securities | Accelerating North American ESS Conversions · FY26 AMPC KRW 359B · 4Q In Line / 2026-02-03 Research
  • [Research] Celltrion (068270/KS) – SK Securities | New Portfolio Mix Expansion · Operating Leverage · H2 Product Launches / 2026-05-07 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Supply Constraints · Earnings Surge / 2026-05-11 Research
  • [Research] LIG D&A (079550) – Yuanta Securities | 4Q25 Review · Conservative 2026E Guidance · Long-term Structural Growth / 2026-02-19 Research
  • [Research] Samsung SDI (006400) – Kyobo Securities | 1Q Trough Passing · ESS Utilization Gains · Humanoid Client Expansion / 2026-03-30 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q1 2026 Earnings Presentation / 2026-04-30 IR Room
  • [IR] SK hynix (000660 / SKHY) – Q3 2025 Earnings Presentation / 2025-10-29 IR Room

[Research] SK hynix (000660 / SKHY) – Daishin | HBM4 · Memory Supply Shortage · Shareholder Returns / 2026-01-02

Posted on January 2, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Daishin Securities

Analyst : Hyeongkeun Ryu (RA: Jiwon Seo)

Investment Rating : BUY (Maintained)

Target Price : 840,000 KRW (Raised)

Core Momentum : HBM4 commercialization and severe commodity memory supply shortages are expected to drive record earnings through the combined strength of HBM and conventional DRAM, while ADR and SPC initiatives support stronger shareholder returns and reduced cycle volatility.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 840,000 KRW (Based on Target P/B 3.2x, Raised)
  • Investment Rating: BUY (Maintained)
  • 2026F Financial Outlook: Revenue 165.95 trillion KRW, Operating Profit 100.78 trillion KRW, Net Income 78.09 trillion KRW
  • EPS: 107,264 KRW (2026F)
  • Valuation Multiples: PER 4.8x, PBR 2.5x, ROE 51.8% (Based on 2026F)

🚀 2. [Market Opportunities & Business Outlook]

  • 4Q25 Preview: Despite disciplined sales growth and bonus provision expenses, 4Q25 operating profit is projected to reach 16.8 trillion KRW, beating market consensus, opening the doors to a historic 100 trillion KRW operating profit era by 2026.
  • HBM Outlook: 2026 shipments are projected to grow 54% YoY to 19.3 billion Gb. Although quality issues regarding HBM4 12-high have been raised, they are deemed solvable, with product qualification expected within 1Q and mass supply starting in 2Q. Nvidia market share is projected to stay solid at 63%.
  • Generic DRAM & NAND: Leveraging unprecedented supply shortages, aggressive pricing policies in 1Q will narrow the generic DRAM ASP gap with competitors, driving strong earnings via the “Twin Engine” effect. Solidigm leads the server QLC market, while headquarters NAND competitiveness improves centered on discrete components.
  • Structural Shifts & Returns: Potential issuance of American Depositary Receipts (ADRs) to reinforce shareholder returns, targeted for materialization within 1Q. Establishment of an SPC to drive structural changes, optimize fundraising in the AI era, and curb cyclical volatility risks.

📝 Editor’s Comment (Perspective)

The analyst views SK hynix as entering a historic 100 trillion KRW operating profit era by 2026, driven by core technology leadership, the “Twin Engine” synergy of HBM and generic DRAM, and structural improvements in NAND. The analyst highlights proactive shareholder return initiatives and structural enhancements via SPC establishment.

To verify this investment thesis, one should track whether actual 4Q earnings beat expectations, if HBM4 12-high qualifications and 2Q shipments proceed on schedule, and how shareholder return measures such as ADR issuance and SPC establishment materialize. These indicators can be monitored through upcoming quarterly reports and regulatory filings via DART.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] LigaChem Biosciences (141080) – IBK Securities | Enhertu Resistance · Clinical Readouts · Tech Transfer / 2025-11-27
Next Post: [Research] SK hynix (000660 / SKHY) – Shinhan | DRAM Supply Shortage · Supplier Pricing Power · HBM3E / 2026-01-05

Related Posts

  • [Research] SK hynix (000660 / SKHY) – DS Investment | Commodity DRAM · ASP Resilience · Earnings Growth / 2026-07-29 Research
  • [Research] Samsung SDI (006400) – Hana Securities | Stepwise Loss Reduction · Strong ESS BBU Shipments · 4Q26 Turnaround / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Legacy Memory Pricing · LTA · ADR / 2026-02-23 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] Samsung SDI (006400) – Kyobo Securities | AI Data Center BBU · Direct CSP Channels · 1Q Earnings Beat / 2026-04-29 Research
  • [Research] LIG D&A (079550) – DS Investment & Securities | Order Expansion · Iraq Cheongung-II Mass Production · Long-term Earnings Growth / 2026-08-07 Research
  • [Research] LigaChem Biosciences (141080) – Kyobo Securities | Pipeline Clinical Progress · IND Filings · Tech Transfer / 2026-04-01 Research
  • [Research] Hanwha Ocean (042660) – Yuanta | Merchant Mix Improvement · CPSP Project Value · MASGA Catalysts / 2026-07-06 Shipbuilding
  • [IR] SK hynix (000660 / SKHY) – Q1 2026 Earnings Presentation / 2026-04-23 IR Room
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | Sanofi Strategy · Grabody B Validity · Muscle Shuttle Expansion / 2026-02-02 Research
  • [Research] Hanwha Ocean (042660) – iM Securities | Merchant Profit Surprise · Special Ship Sentiment · Valuation De-rating / 2026-07-28 Research
  • [Research] LigaChem Biosciences (141080) – Eugene Investment & Securities | Pipeline Clinical Progression · Licensing Revenue · Earnings Turnaround / 2025-02-17 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme